Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma

Interventions

DRUG: XL092
DRUG: Nivolumab

Sponsor

Karie Runcie

Collaborators

[object Object]
[object Object]